Skip to main content

Mirati Therapeutics, MD Anderson Partner to Develop Drugs for KRAS-Mutant Cancers

NEW YORK – Mirati Therapeutics and the MD Anderson Cancer Center on Wednesday said that they have entered a five-year collaboration to advance two of Mirati's KRAS-targeting cancer drugs.

The research and development partnership will specifically focus on MRTX849 (adagrasib) and MRTX1133, which inhibit KRAS G12C mutations and KRAS G12D mutations, respectively. MRTX849 is currently being evaluated in multiple clinical trials for solid tumors, both as a monotherapy and in combination with other agents, while MRTX1133 is currently in preclinical development.

In this partnership, Mirati will provide funding, study materials, and ongoing support, while MD Anderson will contribute its clinical trial infrastructure and expertise. The Houston-based cancer center and San Diego-based drug developer will jointly oversee collaborative studies that evaluate the agents in KRAS-mutated non-small cell lung cancer, colorectal cancer, pancreatic cancer, and gynecological cancers, among other solid tumor types.

"Effective targeted therapies against mutant KRAS could address a major unmet need for many patients," Christopher Flowers, MD Anderson's interim division head of cancer medicine, said in a statement. "Our collaboration with Mirati represents an important opportunity to work toward advancing new treatment options for patients using novel KRAS inhibitors that target two of the most frequent KRAS mutations in common cancers."

The partners did not disclose the financial terms of the collaboration.